Ashrafizadeh, MiladZarrabi, AliBigham, AshkanTaheriazam, AfshinSaghari, YaldaMirzaei, SepidehHashemi, Mehrdad2024-05-192024-05-1920230198-63251098-1128https://doi.org10.1002/med.21971https://hdl.handle.net/20.500.12713/4814Breast cancer is the most malignant tumor in women, and there is no absolute cure for it. Although treatment modalities including surgery, chemotherapy, and radiotherapy are utilized for breast cancer, it is still a life-threatening disease for humans. Nanomedicine has provided a new opportunity in breast cancer treatment, which is the focus of the current study. The nanocarriers deliver chemotherapeutic agents and natural products, both of which increase cytotoxicity against breast tumor cells and prevent the development of drug resistance. The efficacy of gene therapy is boosted by nanoparticles and the delivery of CRISPR/Cas9, Noncoding RNAs, and RNAi, promoting their potential for gene expression regulation. The drug and gene codelivery by nanoparticles can exert a synergistic impact on breast tumors and enhance cellular uptake via endocytosis. Nanostructures are able to induce photothermal and photodynamic therapy for breast tumor ablation via cell death induction. The nanoparticles can provide tumor microenvironment remodeling and repolarization of macrophages for antitumor immunity. The stimuli-responsive nanocarriers, including pH-, redox-, and light-sensitive, can mediate targeted suppression of breast tumors. Besides, nanoparticles can provide a diagnosis of breast cancer and detect biomarkers. Various kinds of nanoparticles have been employed for breast cancer therapy, including carbon-, lipid-, polymeric- and metal-based nanostructures, which are different in terms of biocompatibility and delivery efficiency.eninfo:eu-repo/semantics/closedAccessBreast CancerCancer TherapyClinical ApplicationNanotechnologyStimuli-Responsive NanocarriersReview Article4362115217637165896WOS:0009853859000012-s2.0-85159058380N/A10.1002/med.21971Q1